Mr Richard Allen

All publications

Journal articles

• Kwan A, Stark K, Allen R, Ottewell P & Muthana M (2024) An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy. Medical Research Archives, 12(6).
• Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A & Lewis CE (2023) Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse. Frontiers in Immunology, 14. View this article in WRRO
• Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al (2022) Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
• Juncker-Jensen A, Stavrou N, Moamin M, Nagy M, Allen R, Cox A & Lewis C (2021) 828 Quantifying perivascular immune cells in the stroma of human triple negative breast tumors using deep learning spatial analytics. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A867-A867.
• Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2021) Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, 20(3), 589-601.
• Bishop RT, Marino S, Carrasco G, Li B, Allen RJ, Sparatore A, Ottewell PD, Mollat P, Sims AH, Capulli M , Wang N et al (2020) Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
• Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD & Idris AI (2019) Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 450, 76-87. View this article in WRRO
• Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.

Conference proceedings papers

• Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) Ex vivo-led drug discovery in glioblastoma. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
• Moamin MR, Allen RJ, Stavrou N, Nagy M, Juncker-Jensen A & Lewis CE (2021) Abstract 2720: Perivascular accumulation of immunosuppressive cells in the stroma of human triple negative breast carcinomas: implications for immunotherapy. Cancer Research, Vol. 81(13_Supplement) (pp 2720-2720)
• Moamin MR, Allen RJ, Stavrou N, Nagy M, Juncker-Jensen A & Lewis CE (2021) Perivascular accumulation of immunosuppressive cells in the stroma of human triple negative breast carcinomas: implications for immunotherapy.. CANCER RESEARCH, Vol. 81(13)

Preprints

• Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy, Cold Spring Harbor Laboratory.